×
Endo EBIT Margin 2024-2025 | NDOI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Endo ebit margin from 2024 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
View More
Endo EBIT Margin 2024-2025 | NDOI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Endo ebit margin from 2024 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$75.5B
Zoetis (ZTS)
$67.5B
Takeda Pharmaceutical (TAK)
$46.8B
Daiichi Sankyo, - (DSNKY)
$44.2B
BeOne Medicines - (ONC)
$30.6B
Sandoz Group AG (SDZNY)
$24.9B
Summit Therapeutics (SMMT)
$21B
Merck (MKKGY)
$16.7B
Shionogi (SGIOY)
$14.2B
United Therapeutics (UTHR)
$13.4B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$11B
IPSEN (IPSEY)
$10.2B
Stevanato Group S.p.A (STVN)
$7.7B
Corcept Therapeutics (CORT)
$7.7B
Madrigal Pharmaceuticals (MDGL)
$7.7B
Grifols, S.A (GRFS)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.8B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.3B
Hypermarcas (HYPMY)
$3.2B
Crinetics Pharmaceuticals (CRNX)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
NewAmsterdam Pharma (NAMS)
$2.3B
Centessa Pharmaceuticals (CNTA)
$2.1B
BioCryst Pharmaceuticals (BCRX)
$1.8B
Ocular Therapeutix (OCUL)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.8B